The United Nations has expressed serious concerns over the stagnation of childhood immunisation levels worldwide. Recent data indicates that vaccination rates have stalled, raising alarms about potential outbreaks of preventable diseases.
Faith Villanueva, Co-Chair of the Adult Immunization Committee for Microbiology and Infectious Diseases (PSMID) Inc., emphasised the importance of incorporating…
The Indonesian Society of Internal Medicine (PAPDI) has unveiled a significant update to its adult vaccination recommendations for 2024, marking a major stride towards fortifying public health in Indonesia and across Asia.
AstraZeneca has announced the global discontinuation of its COVID-19 vaccine, Vaxzevria, marking a significant turn in the pandemic’s vaccination strategy.
Discover how the Department of Health in the Philippines has reached a significant milestone by administering measles vaccinations to over 646,000 children nationwide.
Caloocan City Mayor Dale Gonzalo “Along” Malapitan, announced the launch of a free vaccination program to combat various strains of the human papillomavirus (HPV).
The Duke-NUS research team, collaborating with Duke University and the National University of Singapore, conducted a preclinical comparison between nasal and subcutaneous administration of the COVID-19 vaccine. Their findings were published in eBioMedicine. It revealed that the intranasal route not only induces a strong mucosal antibody response but also enhances long-term mucosal and systemic immune protection.
DKSH, a leading market expansion services provider with a focus on Asia, has significantly contributed to the COVID-19 vaccine rollout in Thailand and across Asia.As countries grappled with the logistical challenge of distributing vaccines, DKSH’s Business Unit Healthcare played a pivotal role in ensuring millions received their doses in a timely and effective manner. Dr Varun Sethi, Regional Vice President, Commercial Outsourcing & Cluster Head for APAC, shares the different initiatives by DKSH across Asia.
In a notable development for the healthcare sector, Hilleman Laboratories has inaugurated a US$20 million vaccine production facility in Singapore. This facility, located at Depot Road, is poised to play a crucial role in manufacturing and developing vaccines and biologics.
The new vaccine, trialled in Bangladesh, offers hope against the debilitating dengue virus. The fight against dengue, a persistent health challenge in Asia, is seeing a promising light. A dengue vaccine, trialled in Bangladesh, demonstrates potential in combating the viral disease.
